Jeil Pharmaceutical said on Wednesday that it has released its four-drug combination therapy TelmicanQ for treating high blood pressure and dyslipidemia.

TelmicanQ contains four ingredients --telmisartan, rosuvastatin calcium, ezetimibe, and amlodipine besylate-- in one pill to treat hypertension and dyslipidemia.

Jeil Pharmaceutical believes that the launch of TelmicanQ will be an opportunity to improve the convenience for patients who previously had to take many individual drugs. In this regard, patients can also improve medical compliance to manage multiple diseases like high blood pressure, dyslipidemia, and diabetes simultaneously and more effectively.

According to the Korean Society of Hypertension, there are an estimated 12.1 million patients with hypertension over the age of 20 in Korea, of which, approximately 63 percent of patients are undergoing treatment. And 35 percent of them receive dyslipidemia treatment at the same time.

TelmicanQ demonstrated excellent therapeutic effects in clinical trials conducted on patients with hypertension and dyslipidemia, the company said. It exhibited a 23.06 mm Hg reduction in systolic blood pressure compared to baseline values and a 66.5 percent reduction in low-density lipoprotein (LDL) cholesterol, explained a Jeil Pharmaceutical official.

Additionally, telmisartan, one of the main components of TelmicanQ, has no tetrazole ring due to its chemical structure, so it is independent of nitrosamine and azido impurities that may occur in the process of angiotensin receptor blocker (ARB)-based hypertension treatment.

"TelmicanQ will be an important treatment option for patients with high blood pressure and dyslipidemia," said Jeil Pharmaceutical’s Marketing Project Manager Kim Min-ho. "In the future, various combination drug products containing telmisartan will be added."